AbCellera prices $200M public offering of common shares and pre-funded warrants

AbCellera Biologics Inc.

17,435,897 common shares at $9.75/share and 3,076,926 pre-funded warrants at $9.74999 each.
Gross proceeds ~$200M; net proceeds ~$187M after underwriting discounts and estimated expenses.
Proceeds to fund internal pipeline including lead program ABCL635, plus working capital and general corporate purposes.
Offering expected to close Aug 14, 2026; Jefferies, J.P. Morgan, Cantor, UBS, BMO act as joint book-runners.
Company and insiders subject to 60-day lock-up on share sales following the underwriting agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.